LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe.

    Garnier, Nicolas / Berghout, Joanne / Zygmunt, Aldona / Singh, Deependra / Huang, Kui A / Kantz, Waltraud / Blankart, Carl Rudolf / Gillner, Sandra / Zhao, Jiawei / Roettger, Richard / Saier, Christina / Kirschner, Jan / Schenk, Joern / Atkins, Leon / Ryan, Nuala / Zarakowska, Kaja / Zschüntzsch, Jana / Zuccolo, Michela / Müllenborn, Matthias /
    Man, Yuen-Sum / Goodman, Liz / Trad, Marie / Chalandon, Anne Sophie / Sansen, Stefaan / Martinez-Fresno, Maria / Badger, Shirlene / Walther van Olden, Rudolf / Rothmann, Robert / Lehner, Patrick / Tschohl, Christof / Baillon, Ludovic / Gumus, Gulcin / Gross, Edith / Stefanov, Rumen / Iskrov, Georgi / Raycheva, Ralitsa / Kostadinov, Kostadin / Mitova, Elena / Einhorn, Moshe / Einhorn, Yaron / Schepers, Josef / Hübner, Miriam / Alves, Frauke / Iskandar, Rowan / Mayer, Rudolf / Renieri, Alessandra / Piperkova, Aneta / Gut, Ivo / Beltran, Sergi / Matthiesen, Mads Emil / Poetz, Marion / Hansson, Mats / Trollmann, Regina / Agolini, Emanuele / Ottombrino, Silvia / Novelli, Antonio / Bertini, Enrico / Selvatici, Rita / Farnè, Marianna / Fortunato, Fernanda / Ferlini, Alessandra

    PloS one

    2023  Volume 18, Issue 11, Page(s) e0293503

    Abstract: Since 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic "window of opportunity". Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research ... ...

    Abstract Since 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic "window of opportunity". Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research project, which resulted of a joint effort between the European Union Commission and the European Federation of Pharmaceutical Industries and Associations. It focuses on genetic newborn screening and artificial intelligence-based tools which will be applied to a large European population of about 25.000 infants. The neonatal screening strategy will be based on targeted sequencing, while whole genome sequencing will be offered to all enrolled infants who may show early symptoms but have resulted negative at the targeted sequencing-based newborn screening. We will leverage artificial intelligence-based algorithms to identify patients using Electronic Health Records (EHR) and to build a repository "symptom checkers" for patients and healthcare providers. S4C will design an equitable, ethical, and sustainable framework for genetic newborn screening and new digital tools, corroborated by a large workout where legal, ethical, and social complexities will be addressed with the intent of making the framework highly and flexibly translatable into the diverse European health systems.
    MeSH term(s) Infant, Newborn ; Humans ; Child ; Neonatal Screening/methods ; Rare Diseases/diagnosis ; Rare Diseases/epidemiology ; Rare Diseases/genetics ; Artificial Intelligence ; Digital Technology ; Europe
    Language English
    Publishing date 2023-11-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0293503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Is age-related macular degeneration associated with stroke among elderly americans?

    Liao, Duanping / Mo, Jingping / Duan, Yinkang / Klein, Ronald / Scott, Ingrid U / Huang, Kui A / Zhou, Haibo

    The open ophthalmology journal

    2008  Volume 2, Page(s) 37–42

    Abstract: Objective: To investigate whether age-related macular degeneration (AMD) is associated with the development of ischemic and hemorrhagic stroke among elderly Americans.: Design: Population-based cohort study.: Participants: The five percent random ... ...

    Abstract Objective: To investigate whether age-related macular degeneration (AMD) is associated with the development of ischemic and hemorrhagic stroke among elderly Americans.
    Design: Population-based cohort study.
    Participants: The five percent random sample of 2000-2003 Medicare enrollees was obtained. The cohort (n=1,519,086) consisted of enrollees who were aged 65 or older at the first two-year (January 1, 2000 to December 31, 2001).
    Methods: Baseline demographic variables and chronic conditions (AMD and type, history of myocardial infarction (MI), stroke, hypertension, and diabetes) were defined based on the occurrence of relevant ICD-9 codes in relevant diagnosis fields of the baseline Medicare Data. We excluded 215,900 persons who had a diagnosis of MI or stroke during baseline period to form a cohort of 1,303,186 individuals who were free of major cardio-cerebral vascular disease (CVD) at baseline.
    Main outcome measures: In two years of follow-up (January 1, 2002 to December 31, 2003), a total of 89,501 incident stroke cases were identified, including 80,018 ischemic, 7048 hemorrhagic, and 2,435 stroke cases of both types.
    Results: Baseline mean age was 75 years (Standard Divination=7.7), with 60% women and 88% whites. The prevalence of AMD was 10.6%, with 19.7% being neovascular AMD and 80.3% being non-neovascular AMD. Baseline age, gender, race, hypertension, and diabetes adjusted 2-year incident odds ratios and 95% confidence internal of stroke associated with AMD were 1.31 (1.26, 1.36) for neovascular AMD, 1.18 (1.15, 1.21) for non-neovascular AMD, and 1.21 (1.18, 1.23) for either neovascular or non-neovascular AMD.
    Conclusion: The findings are suggestive of an association between AMD, especially neovascular AMD, and incident stroke, independent of demographic factors and co-morbidity. These findings, if confirmed by other studies that control for smoking and other lifestyle covariables not measured in this study, suggest the possibility of shared common antecedents between stroke and AMD.
    Language English
    Publishing date 2008-03-08
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 2395991-5
    ISSN 1874-3641 ; 1874-3641
    ISSN (online) 1874-3641
    ISSN 1874-3641
    DOI 10.2174/1874364100802010037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Guidelines for submitting adverse event reports for publication.

    Kelly, William N / Arellano, Felix M / Barnes, Joanne / Bergman, Ulf / Edwards, Ralph I / Fernandez, Alina M / Freedman, Stephen B / Goldsmith, David I / Huang, Kui A / Jones, Judith K / McLeay, Rachel / Moore, Nicholas / Stather, Rosie H / Trenque, Thierry / Troutman, William G / van Puijenbroek, Eugene / Williams, Frank / Wise, Robert P

    Drug safety

    2007  Volume 30, Issue 5, Page(s) 367–373

    Abstract: Publication of case reports describing suspected adverse effects of drugs and medical products that include herbal and complementary medicines, vaccines, and other biologicals and devices is important for postmarketing surveillance. Publication lends ... ...

    Abstract Publication of case reports describing suspected adverse effects of drugs and medical products that include herbal and complementary medicines, vaccines, and other biologicals and devices is important for postmarketing surveillance. Publication lends credence to important signals raised in these adverse event reports. Unfortunately, deficiencies in vital information in published cases can often limit the value of such reports by failing to provide enough details for either (i) a differential diagnosis or provisional assessment of cause-effect association, or (ii) a reasonable pharmacological or biological explanation. Properly described, a published report of one or more adverse events can provide a useful signal of possible risks associated with the use of a drug or medical product which might warrant further exploration. A review conducted by the Task Force authors found that many major journals have minimal requirements for publishing adverse event reports, and some have none at all. Based on a literature review and our collective experience in reviewing adverse event case reports in regulatory, academic, and industry settings, we have identified information that we propose should always be considered for inclusion in a report submitted for publication. These guidelines have been endorsed by the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP) and are freely available on the societies' websites. Their widespread distribution is encouraged. ISPE and ISoP urge biomedical journals to adopt these guidelines and apply them to case reports submitted for publication. They also encourage schools of medicine, pharmacy, and nursing to incorporate them into the relevant curricula that address the detection, evaluation, and reporting of suspected drug or other medical product adverse events.
    MeSH term(s) Adverse Drug Reaction Reporting Systems/standards ; Data Collection/statistics & numerical data ; Epidemiologic Methods ; Humans ; Information Storage and Retrieval/statistics & numerical data ; Periodicals as Topic/standards ; Product Surveillance, Postmarketing
    Language English
    Publishing date 2007-02-09
    Publishing country New Zealand
    Document type Guideline ; Journal Article
    ZDB-ID 1018059-x
    ISSN 1179-1942 ; 0114-5916
    ISSN (online) 1179-1942
    ISSN 0114-5916
    DOI 10.2165/00002018-200730050-00001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top